0001610717-26-000041.txt : 20260204 0001610717-26-000041.hdr.sgml : 20260204 20260204162527 ACCESSION NUMBER: 0001610717-26-000041 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260202 FILED AS OF DATE: 20260204 DATE AS OF CHANGE: 20260204 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BELVIN MARCIA CENTRAL INDEX KEY: 0001970752 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37587 FILM NUMBER: 26598605 MAIL ADDRESS: STREET 1: C/O CYTOMX THERAPEUTICS, INC. STREET 2: 151 OYSTER POINT BLVD., STE. 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CytomX Therapeutics, Inc. CENTRAL INDEX KEY: 0001501989 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 273521219 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650.515.3185 MAIL ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 form4.xml X0508 4 2026-02-02 0001501989 CytomX Therapeutics, Inc. CTMX 0001970752 BELVIN MARCIA C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD., STE. 400 SOUTH SAN FRANCISCO CA 94080 true SVP, Chief Scientific Officer false Common Stock 2026-02-02 4 A 0 60000 0 A 332252 D Stock Option (Right to Buy) 6.09 2026-02-02 4 A 0 250000 0 A 2036-02-01 Common Stock 250000 250000 D Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date. Includes 218,958 RSUs. 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. /s/ Christopher Ogden, as Attorney-in-Fact for Marcia Belvin 2026-02-04